The articles collated for this issue will largely be based on presentations at the Mycology 2021 in London, which, because of the impact of COVI-19 restrictions, will be held entirely as a virtual congress.
LINK:
mycologyconference.co.uk The thematic is to combine clinical and academic mycology in one meeting and to promote networking that can ultimately make a difference to the clinical challenges of patients with fungal diseases. We welcome articles addressing the session themes of:
- Host susceptibility
- IFD prophylaxis and management in Haemato-oncology
- IFD in solid organ transplantation
- the role of mycology societies/organisations
- diagnostics - lateral flow, PCR, T2MR, resistance testing, NGS
- fungal adaptation to the host environment
- Mycobiome and NGS
- Fungal infections in CF and bronchiectasis
- Novel antifungal drugs
- Influenza, SARS-CoV-2 and aspergillosis
- Educational clinical cases
Topic editor declare the following Conflict Of Interest:
S. Agrawal - Consultancy work for, and research grants form, Gilead Sciences Ltd, Pfizer Ltd
N. Gow - research funded by Gilead Sciences.
L White - Consultancy work for Gilead Sciences Ltd, Pfizer Ltd and F2G Ltd. Diagnostic collaborations with IMMY, Bruker, Associates of Cape Cod and Dynamiker.
